Contact us

A leading European firm of Intellectual Property specialists

 

We provide commercially focused, creative advice on obtaining, enforcing and exploiting intellectual property rights including patents, trade marks and designs to a wide range of clients who enjoy our straight forward approach and flexible working practices.

 
Home

SPOTLIGHT ON...

At Mewburn Ellis, our qualified patent and trade mark attorneys, along with our legal services team and dispute resolution team, assist our clients across the entire range of IP services in numerous diverse industry sectors, some of which are listed below.

FIND THE INFORMATION YOU NEED

Brexit

It's business as usual for Mewburn Ellis despite the decision for the UK to end its membership of the EU.  We consider the effect of the decision on intellectual property.  

MEDTECH

With a medtech team including patent attorneys drawn from all technical disciplines, you can rest assured that you will be working with a specialist that truly understands your technology.

PHARMACEUTICAL

The worldwide recognition achieved by our large pharmaceutical team will give you the confidence that your commercially valuable intellectual property is in the best hands.

Transport

Our experience advising a wide range of clients, from UK-based component manufacturers to multi-national vehicle manufacturers, means we can help you ensure that you develop an appropriate IP strategy to meet your business needs.

FOOD & BEVERAGE

Many restaurateur, food producer and brewery clients have enjoyed considerable success working with our trade mark and patent attorneys to protect their brands and innovations.

CASE STUDIES

See examples of how, at Mewburn Ellis, we strive to help our clients to use intellectual property to achieve their commercial objectives.

OUR OFFICES

LONDON

t: +44 (0)20 7776 5300

BRISTOL

t: +44 (0)117 945 1234

CAMBRIDGE

t: +44 (0)1223 420383

MANCHESTER

t: +44 (0)161 247 7722

View map & contact details

LATEST NEWS & EVENTS

BerGenBio release positive new preclinical study data in development of their BGB324 AXL-inhibitor

BerGenBio a clinical stage biopharmaceutical company focused on developing innovative drugs for aggressive drug resistant cancers, have released important new preclinical study data on its first-in-class AXL inhibitor, BGB324.

PIPLA EVENT OCTOBER 2016

Joe Lenthall will be speaking at the Philadelphia Intellectual Property Law Association (PIPLA) CLE breakfast event on Thursday, October 12, 2016 in Philadelphia.

View more